Iron oxide nanoparticles induce cytokine secretion in a complement-dependent manner in a human whole blood model

Susann Wolf-Grosse1
Anne Mari Rokstad1,2
Syed Ali4
John D Lambris5
Tom E Mollnes2,6,9
Asbjørn M Nilsen1,1
Jørgen Stenvik1,2,*

1Department of Cancer Research and Molecular Medicine, 2Centre of Molecular Inflammation Research (CMIR), Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway; 3Central Norway Regional Health Authority, Stjørdal, Norway; 4Division of Neurotoxicology, US FDA/National Center for Toxicological Research, Jefferson, AR; 5Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA; 6Department of Immunology, Oslo University Hospital, Rikshospitalet, Oslo, Norway; 7Research Laboratory, Nordland Hospital, Bodo, 8K.G. Jebsen Thrombosis Research and Expertise Centre, University of Tromsø, Tromsø, Norway

*These authors contributed equally to this work

Abstract: Iron oxide nanoparticles (IONPs) are promising nanomaterials for biomedical applications. However, their inflammatory potential has not been fully established. Here, we used a lepirudin anti-coagulated human whole blood model to evaluate the potential of 10 nm IONPs to activate the complement system and induce cytokine production. Reactive oxygen species and cell death were also assessed. The IONPs activated complement, as measured by C3a, C5a and sC5b-9, and induced the production of pro-inflammatory cytokines in a particle-dose dependent manner, with the strongest response at 10 µg/mL IONPs. Complement inhibitors at C3 (compstatin analog Cp40) and C5 (eculizumab) levels completely inhibited complement activation and secretion of inflammatory mediators induced by the IONPs. Additionally, blockade of complement receptors C3aR and C5aR1 significantly reduced the levels of various cytokines, indicating that the particle-induced secretion of inflammatory mediators is mainly C5a and C3a mediated. The IONPs did not induce cell death or reactive oxygen species, which further suggests that complement activation alone was responsible for most of the particle-induced cytokines. These data suggest that the lepirudin anti-coagulated human whole blood model is a valuable ex vivo system to study the inflammatory potential of IONPs. We conclude that IONPs induce complement-mediated cytokine secretion in human whole blood.

Keywords: iron oxide nanoparticles, human whole blood, complement activation, cytokines, reactive oxygen species, complement inhibitors

Background

Due to their magnetic properties, iron oxide nanoparticles (IONPs) have been explored for their use in biomedical applications, for example, as contrast agent for MRI, in tissue repair, in targeted drug delivery systems and for induced hyperthermia cancer treatment. Such applications might involve intravenous injection. Thus, it is of importance to assess the interactions of these nanoparticles with cellular and humoral components of the innate immune system in the blood.

On contact with blood, nanoparticles may be recognized by elements of the immune system, in particular, the plasma cascades like the complement, coagulation and contact system. It has long been known that the plasma cascade systems not only interact with each other, but also exhibit extensive crosstalk with the cellular elements in the blood.

The complement system, which consists of over 40 plasma and membrane-bound proteins (receptors and regulators), destroys and removes foreign substances, either directly or by activating leukocytes and initiating pro-inflammatory
responses via mediators such as cytokines. In general, complement activation can be initiated by either the classical, lectin or alternative pathway. Activation of either pathway results in the turnover of the C3 protein, which is followed by the production of the anaphylatoxins C3a and C5a, and the formation of the C5b-9 complex (also named terminal complement complex or membrane attack complex). Uncontrolled complement activation and pro-inflammatory responses induced by biomaterials or nanomaterials may initiate adverse infusion-related reactions.

Complement activation can play a major role in immune recognition of nanoparticles, which is dependent on particle characteristics, such as size, shape and surface properties. Previous studies demonstrated complement activation by dextran-coated superparamagnetic iron oxide nanoparticles (SPIONs) and nanoworms in human serum and complement-mediated SPIO nanoworm recognition and uptake by leukocytes. Furthermore, IONPs may induce cytokine production in various immune cells. For example, γ-Fe₂O₃ nanoparticles can increase TNF in RAW264.7 cells and carboxydextran-coated Fe₃O₄/Fe₂O₃ nanoparticles induced TNF in THP-1 cells. Moreover, non-coated and polycrylic acid-coated IONPs induced IL-1ß, IL-8, IL-6, TNF and IL-10 in primary human blood cells and amino-polivinyl alcohol-coated SPION increased the secretion of IL-1ß, IL-4, IL-8, IL-6, MIP-1ß and RANTES in whole blood samples. In contrast, we did not observe pro-inflammatory cytokine production by IONPs in primary human monocytes, which might be due to different properties of the IONPs and different cell types used.

In order to characterize the effects of IONPs in a more physiologically complex system, we used an ex vivo human whole blood model in the present study. This model uses the hirudin analog lepirudin as anti-coagulant, which specifically inhibits thrombin, but has no effect on the complement system, induction of pro-inflammatory cytokines, or the interplay between them. Previous studies used this model to examine cholesterol crystal-induced inflammasome activation, or to study the effects of implantable sensors and polycation-containing microspheres. It has also been used to study polystyrene nanoparticles, but this human whole blood model has not been previously used to evaluate the biological effects of IONPs.

Here, we report the effects of IONPs in human whole blood with a focus on complement activation and induction of cytokines. We also evaluated if the IONPs induced cytotoxicity as measured by the production of reactive oxygen species (ROS) and cell viability.

**Methods**

**Nanoparticle suspensions**

The 10 nm sized IONPs with an amphiphilic polymer coating (catalog numbers SHP-10–10 and SXP-10-05) were purchased from Ocean Nanotech, LLC (Springdale, AR, USA). The IONPs are coated with a monolayer of oleic acid and a monolayer of amphiphilic polymer. The reactive group on the surface is carboxylic acid (Figure S1).

**Characterization of IONPs**

The size, shape, chemical composition, hydrodynamic diameter and zeta potential of the IONPs have been previously characterized. In the present study, additional measurements of the particles’ hydrodynamic diameter in phosphate-buffered saline (PBS) without Ca²⁺/Mg²⁺ have been performed. Transmission electron microscopy (TEM) was used to assess the size and agglomeration status of the IONPs in human lepirudin-plasma incubated at 37°C for 2 h. Formvar-coated copper grids were placed on a drop of the IONP sample (100 µg/mL) for 5 min. The grids were gently drained with filter paper and the sample was subsequently inspected without further treatment using a JEOL TEM (JEOL, Tokyo, Japan) at 80 kV.

We verified in our previous study that the particles were not contaminated with endotoxin/lipopolysaccharide (LPS) or Toll-like receptor 2 ligand.

**Human whole blood model**

An ex vivo lepirudin-based human whole blood model, as first described by Mollnes et al., was adapted to assess the inflammatory effects of IONPs in a complex biological environment. The ex vivo whole blood model is presently one of the systems to closest mimic an in vivo situation. This model uses lepirudin as an anti-coagulant as it specifically inhibits thrombin, but has no effect on the activation of the complement system, as opposed to heparin. Whole blood from voluntary, healthy donors was collected in low activating polypropylene vials (Nunc 4.5 mL) containing lepirudin (50 µg/mL). Immediately afterward, blood (250 µL) was incubated with 50 µL PBS and 50 µL PBS containing IONPs (1, 10 and 100 µg/mL) in 1.8 mL polypropylene vials (Nunc). Zymosan (Zym; 10 µg) served as positive control for complement activation. The samples were incubated for 2, 4 or 6 h at 37°C in a heat cabinet under continuous, slow rotation around the vertical axis using a Rock’n Roller (Labinco B.V., Breda, the Netherlands). In the experiments with the complement inhibitors, blood was...
pre-incubated for 7 min with C3 inhibitor compstatin analog Cp40 (final concentration 20 µM), a 14-amino acid cyclic peptide ((D)Tyr-Ile-[Cys-Val-Trp(Me)]-Gln-Asp-Trp-Sar-Ala-His-Arg-Cys]-mIle-NH2; synthesized as previously described20), C5 inhibitor Soliris® (eculizumab; Alexion Pharmaceuticals, Zürich, Switzerland; final concentration 100 µg/mL), C5a receptor antagonist (C5aRA) PMX53 (final concentration 10 µg/mL; as previously described21) or C3a receptor antagonist (C3aRA; final concentration 50 µM; kindly provided by Robert S Ames) or PBS in the ratio blood to inhibitor or PBS equal to 5:1. IONPs and controls were then added to the pre-incubated blood and further incubated for various time periods. At the end of the incubation time, further complement activation was inhibited with ethylenediaminetetraacetic acid (EDTA) at a final concentration of 10 mM and plasma was prepared by centrifugation at 1,880g for 15 min. Plasma samples were stored at −20°C until analysis. To assess the baseline values (T0) for cytokine production and complement activation, one blood sample was immediately centrifuged at 1,880g for 15 min after blood withdrawal and addition of EDTA.

**Complement activation assays**

C3a and C5a were assessed by measuring the amount of C3a/ C3a desArg and C5a/C5a desArg using the C3a PlusEIA kit from MicroVue (Quidel, San Diego, CA, USA) and the C5a enzyme-linked immunosorbent assay (ELISA) kit II from BD BioSciences (San Diego, CA, USA), respectively.

The terminal soluble C5b-9 complement complex (sC5b-9) was measured by an ELISA. This assay, modified after,22 is based on a monoclonal capture antibody, which is specific for a neoepitope exposed in C9 after activation. Briefly, 96-well plates (Costar 3690, high-binding polystyrene plates) were coated with the capture monoclonal antibody aE11. After sample incubation and a washing step, a second biotinylated anti-C6 antibody (mAb 9C4) was added. Following another washing step, Streptavidin-horse radish peroxidase and tetramethylbenzidine substrate were added and the absorbance was measured at 450 and 655 nm (for background correction).

**Cytokine analysis**

Cytokine production in plasma samples was measured using a 17-plex cytokine assay (BioPlex Multiplex human cytokine 17-plex panel; Bio-Rad, Hercules, CA, USA) containing the following analytes: IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8 (CXCL8), IL-10, IL-12 (p70), IL-13, IL-17, granulocyte colony stimulating factor, granulocyte macrophage colony stimulating factor, interferon gamma, MCP-1 (also known as CCL2), MIP-1β (also known as CCL4) and TNF-α. The analysis was performed according to the manufacturer’s instructions. A Bio-Plex 200 instrument (Bio-Rad) and its software (Bio-Plex 6.1) were used for analysis.

**Cell viability**

Cell viability in the whole blood samples was determined using fixable viability dye eFluor780 (eBioscience, Affymetrix, Santa Clara, CA, USA). Briefly, following incubation of whole blood samples with the various stimuli and controls, 100 µL blood were added to new Nunc tubes containing 5 µL anti-CD14-FITC and 1 µL fixable viability dye eFluor780. The samples were incubated for 30 min on ice and then washed 2x with PBS. Following lysis of red blood cells with BD FACS lysing solution, the samples were resuspended in PBS, before they were analyzed using a FACSCalibur flow cytometer (BD BioSciences).

**Reactive oxygen species**

Oxidative burst in whole blood samples was determined using the Phagoburst kit (Glycotope Biotechnology, Heidelberg, Germany), with small changes to the manufacturer’s protocol. Whole blood samples were incubated with PBS, IONPs and Zymosan for 2 or 4 h, whereas opsonized *Escherichia coli* (provided in the kit) was incubated for 10 min according to the manufacturer’s instructions. Following lysis of red blood cells and staining with anti-CD14-PE for 15 min after blood withdrawal and addition of EDTA.

**Statistical analysis**

Statistical analysis was done with GraphPad Prism 6 (GraphPad Software Inc., La Jolla, CA, USA). The data was analyzed using one-way, repeated measures analysis of variance with Dunnett’s multiple comparison test. In order to eliminate uncertainties concerning normal distribution of the data due to a low sample number between 3 and 14, the data was log transformed before analysis. Results were considered statistically significant when P<0.05.

**Ethics**

The use of human whole blood for our experiments was approved by the Regional Committee for Medical and Health Research Ethics in Central Norway (REC Central), The Norwegian Ministry of Education and Research, 2009/2245. Experiments were conducted according to their regulations.
and guidelines. Informed written consent was obtained from each voluntary donor prior to blood sampling.

Results

Physicochemical characterization of the IONPs

An initial characterization of the IONPs as to their hydrodynamic diameter, zeta potential and chemical composition was done in our previous study\(^1\) and is shown in Table 1. In the present study, we additionally determined the hydrodynamic diameter of the IONPs in PBS as the IONPs were dispersed in PBS before adding to the whole blood samples. The particles retained almost the same hydrodynamic diameter in PBS as in water (as supplied) (Table 1). Furthermore, visual examination of the particle size and agglomeration status in lepirudin-plasma using TEM confirmed the primary particle size of 10 nm and indicated only few particle agglomerates with sizes up to 100 nm (Figure 1).

Table 1 Physicochemical characterization of the 10 nm iron oxide nanoparticles

<table>
<thead>
<tr>
<th>IONPs</th>
<th>Hydrodynamic diameter (nm) (polydispersity index)</th>
<th>Zeta potential</th>
<th>Chemical composition</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Water (as supplied)</td>
<td>Phosphate-buffered saline</td>
<td>Water (as supplied)</td>
</tr>
<tr>
<td>10 nm</td>
<td>21.2±0.1 (0.133)(^a)</td>
<td>22.7±0.6 (0.132)</td>
<td>−53.3(^a)</td>
</tr>
</tbody>
</table>

Notes: *According to Grosse et al.\(^1\)

Cytokine response in human whole blood

We further analyzed the levels of 17 cytokines in the plasma following IONP exposure. A significant increase of IL-1\(\beta\), TNF, IL-6, MCP-1, IL-8 and MIP-1\(\beta\) was apparent after 6 h (Figure 3). The other cytokines were either below the detection limit or not significantly induced by IONPs after 6 h, and are thus not shown. The IL-1\(\beta\), TNF, IL-6 and IL-8 secretion correlated with the particle-induced complement activation, with an induction optimum at 10 \(\mu\)g/mL IONPs (Figure 2). The chemokines MCP-1 and MIP-1\(\beta\) showed a gradual dose-dependent increase, with the highest potency at 100 \(\mu\)g/mL IONPs (Figure 3). The activation optimum for MCP-1 and MIP-1\(\beta\) was thus different from the complement peaking at 10 \(\mu\)g/mL IONPs. The cytokine secretion was initially measured after 2, 4 and 6 h (Figure S2). Following IONP exposure, the earliest cytokine induction above saline control was apparent at 4 h for IL-8 and MIP-1\(\beta\).

![Figure 1](https://www.dovepress.com/)

**Figure 1** Size characterization of the IONPs.

**Notes:** Transmission electron microscopy images of the 10 nm IONPs suspended in phosphate-buffered saline and incubated in human lepirudin-plasma for 2 h at 37°C. Two representative images are shown, indicating IONP size and agglomeration status. The IONPs were mainly visible as single particles (arrows). Only very few particle agglomerates (arrow heads) were found.

**Abbreviation:** IONPs, iron oxide nanoparticles.
Particle-induced cytokine response with complement inhibitors

In order to test if the particle-induced cytokine production was complement mediated, we used two inhibitors of the complement components C3 and C5, respectively, and further on receptor antagonists for C3aR and C5aR1. The C3 inhibitor compstatin analog Cp40 significantly decreased the particle-induced production of all cytokines examined (Figure 4). In addition, statistically significant inhibition of the IL-1β, TNF, IL-6 and IL-8 response by compstatin analog Cp40 was detected in the PBS control samples, consistent with the background activation of complement induced by the polypropylene vials. The particle-induced cytokine induction exceeded the background activation, thus the results altogether indicate that complement activation was responsible for the particle-induced cytokine production.

Inhibition of C5 activation with eculizumab significantly decreased the production of MCP-1 and IL-8 (Figure 5). Moreover, TNF, IL-6 and IL-1β were lower, though not significant, after treatment with eculizumab. In contrast, the particle-mediated MIP-1β production appeared to be unaffected by the addition of the C5 inhibitor. It has to be...
noted that the particle-induced cytokine production in these experiments, utilizing another set of donors, was not as strong as in the experiments with compstatin analog Cp40 (Figure 4). We conclude that the particle-mediated activation of C5 is involved in the cytokine response induced by IONPs. Of note, compstatin analog Cp40 and eculizumab also completely abolished the sC5b-9 formation by Zymosan exposure, included as a control (Figure S3).

To further validate our results indicating that the particle-induced complement activation triggers the cytokine response, we assessed the cytokine secretion in the presence of two complement receptor antagonists. For these experiments, eculizumab was included as an internal control and we chose 10 μg/mL IONPs, as this particle concentration induced the strongest cytokine response. Blocking of either the C3a receptor (C3aR) or the C5a receptor (C5aR1) significantly reduced the particle-induced IL-6, MCP-1 and IL-8 production (Figure 6). Additionally, the production of TNF and IL-1β was abolished by addition of C5aRA. In contrast, the MIP-1β production was unaffected by both receptor antagonists as well as eculizumab (Figure 6). These data indicate that complement activation, mainly via C5aR activation, but also involving the C3aR, is responsible for the particle-induced cytokine responses.

**ROS production and viability in human whole blood**

We finally assessed if the production of ROS or loss of viability could play a role in IONP-mediated complement activation and cytokine production. IONPs did not significantly increase ROS in monocytes or granulocytes compared with the PBS control, while addition of opsonized *E. coli* and Zymosan elicited strong responses within 10 and 120 min of incubation, respectively, in both cell types (Figure 7A).

Incubation of human whole blood with PBS for 6 h resulted in ~20% dead or dying monocytes and granulocytes (Figure 7B). Addition of IONPs did not significantly change the percentage of dead monocytes. There was a slightly higher number of dying granulocytes with high concentrations of IONPs, but the difference was not significant. In contrast, stimulation with Zymosan gave ~50% dead or dying cells (*P*<0.05), while *E. coli* did not after 6 h incubation in whole blood.

**Discussion**

We examined the biological effects of 10 nm IONPs on complement activation, cytokine induction, ROS and cell viability in human whole blood. The lepirudin anti-coagulated human blood model is a complex biological model containing various humoral factors and cell types close to an in vivo environment. Thus, this in vivo model is particularly suited for studying complement activation and its consequences in inflammatory crosstalk. To the best of our knowledge, this is the first study that investigates the inflammatory effects of IONPs in human whole blood.

Previous studies associated nanoparticulate systems, including IONPs, with in vivo complement activation and complement-related side effects. Here, we showed that...
IONPs provoked complement activation resulting in the generation of the anaphylatoxins C3a and C5a as well as the soluble terminal complement complex sC5b-9 in an ex vivo human whole blood model. Moreover, the IONPs induced the secretion of pro-inflammatory cytokines in whole blood from healthy donors. Particle contamination with endotoxin/LPS or bacterial lipoproteins could potentially be the reason for the cytokine production. However, as previously demonstrated, contamination of the IONPs can be excluded.

By using specific inhibitors of complement proteins and cell surface receptors, we investigated if there is a direct link between complement activation and secretion of cytokines. Our results demonstrated that both C3a and C5a are major contributors to the release of pro-inflammatory cytokines, since both inhibition of C3 and C5 as well as C3aR and

**Figure 4** The effect of C3 inhibitor compstatin analog Cp40 on cytokine response in plasma after 6 h incubation of anti-coagulated human whole blood with IONPs.

**Notes:** Plasma baseline (T0) values (pg/mL): 0.9±0.6 (IL-1β), 14±6.6 (TNF), 1.7±0.6 (IL-6), 4.5±1.0 (IL-8), 31±2.8 (MCP-1) and 37±7.5 (MIP-1β). Data are expressed as mean ± standard error of the mean (n=4) of separate experiments with different donors. *Statistical significance (P<0.05) compared with untreated PBS control and #statistical significance compared with the same treatment without C3 inhibitor compstatin analog Cp40.

**Abbreviations:** IONPs, iron oxide nanoparticles; PBS, phosphate-buffered saline.
C5aR1 blockers significantly reduced IONP-induced IL-1β, TNF, IL-6, IL-8, MCP-1 and MIP-1β production. It has previously been demonstrated that biomaterials, like polyvinyl chloride tubing, induced complement-dependent secretion of chemokines IL-8, MIP-1α and MCP-1. Furthermore, a complete dependency on complement has previously also been found for the inflammatory cytokines IL-1β, TNF, IL-6, IL-8, MIP-1β and MCP-1 during exposure to poly-L-lysine containing microcapsules. To the best of our knowledge, this is the first study that showed that engineered nanoparticles, like IONPs, induce cytokine secretion in a complement-dependent manner, thus underscoring the potential of inhibiting complement to prevent detrimental coagulation- and inflammation-related effects induced by nanoparticles.

**Figure 5** The effect of C5 inhibitor eculizumab on cytokine response in plasma after 6 h incubation of anti-coagulated human whole blood with IONPs.

Notes: Plasma baseline (T0) values (pg/mL): 1.8±0.5 (IL-1β), 14±6.2 (TNF), 1.1±0.7 (IL-6), 4.1±1.2 (IL-8), 43±14.7 (MCP-1) and 35±9.6 (MIP-1β). Data are expressed as mean ± standard error of the mean (n=3) of separate experiments with different donors. *Statistical significance (P<0.05) compared with untreated PBS control and †statistical significance compared with the same treatment without C5 inhibitor eculizumab.

Abbreviations: IONPs, iron oxide nanoparticles; PBS, phosphate-buffered saline.
The C3 inhibitor compstatin analog Cp40 completely inhibited the cytokine response, whereas C5 inhibitor eculizumab only partly reduced the production of the inflammatory mediators, which is in agreement with previous findings.26,27 While compstatin analog Cp40 inhibits both the formation of C3a and C5a, eculizumab only inhibited the formation of C5a, thus our data could be explained by a dual involvement of C3a and C5a for optimal cytokine response. In a study by Orning et al,27 the differences between compstatin and eculizumab were also shown to be connected to the C3b/iC3b formation with subsequent cell-adhesion (by complement receptor CR3). Although this study investigated non-phagocyttable microcapsules and the effects of cell adhesion, it also illustrates the possibility for the involvement of other complement activating products such as C3b/iC3b.
In the present study, the cytokine response was generally mostly due to C5aR1 activation by C5a. The complement cleavage byproduct and anaphylatoxin C5a is the most potent pro-inflammatory mediator released upon complement activation and far more potent than C3a. It is able to induce monocyte and neutrophil chemotaxis and activation, epithelial and endothelial cell leakage, mast cell degranulation and production of cytokines and chemokines. By binding to its main C5a receptor, C5aR1, C5a initiates signaling cascades that result in NFκB activation and ROS production. Our results show that low concentrations of IONPs are able to induce the generation of C5a, which was a major driver of the observed cytokine response.

Unexpectedly, high concentrations of IONPs had a weaker effect on C5a generation compared with lower particle concentrations. This “concentration effect” was also observed for C3a and sC5b-9, and corresponded well with the cytokine profile of IL-1β, TNF, IL-6 and IL-8. In contrast, MCP-1 and MIP-1β levels increased with increasing particle concentrations. This suggests that additional, yet unidentified, mechanisms contribute to the induction of these particular cytokines.

The stability of a dispersion decreases with increasing concentration and high particle concentrations could give rise to cytotoxicity. However, our results suggest that neither particle agglomeration nor cytotoxicity were main factors influencing the cytokine response due to treatment of human whole blood with IONPs. It cannot be excluded that complement factors and regulators adsorbed to the particles at the highest IONP concentration examined, thus counteracting the stimulatory effects at lower concentrations. Such a negative regulatory effect might be similar to the adsorption and inactivation of LPS that we previously described using the same IONPs in cell culture.

In order to examine if the cytokine response in our study was accompanied by ROS production, we measured intracellular ROS in the whole blood samples after 2 and 4 h. The IONPs did not significantly increase ROS compared with the control samples, which is in agreement with previous findings. However, our results are in contrast to...
other studies that show IONP-induced ROS production.\textsuperscript{32–35} Possible explanations for the discrepancies include one or more of the following factors: different types and sizes of IONPs used; different surface properties (eg, surface coatings) of the IONPs that affect the degradation potential and thus the exposure to the naked iron oxide core and the liberation of iron ions that might induce ROS;\textsuperscript{50} different cell types used; higher IONP concentration; different (mostly longer) incubation times after which ROS production was measured and/or different methods for assessing intracellular ROS.

We conclude that the IONPs examined here induced a pro-inflammatory response via complement-mediated cytokine secretion without signs of cytotoxicity and ROS production in human whole blood. Furthermore, the ex vivo human whole blood model is a highly suitable model for studying the immunomodulatory effects of engineered nanoparticles. Although this model lacks the complexity of a whole organism, it has major advantages over monoculture models: it minimizes nanoparticle sedimentation, which has shown to have great influence in in vitro nanotoxicity studies,\textsuperscript{36} and, most importantly, it allows for intercellular communication and crosstalk with the protein cascades in the blood that are important for initial inflammatory responses.

Acknowledgments

The authors thank all volunteers for donating blood samples. Furthermore, we thank Nan E Tostrup Skogaker for her technical support with TEM, which was conducted at the Cellular and Molecular Imaging Core Facility (CMIC), Norwegian University of Science and Technology.

SW-G was financed by NanoLab, Norwegian University of Science and Technology. The Research Council of Norway is acknowledged for the support to the Norwegian Micro- and Nano-Fabrication Facility, NorFab, project number 245963/F50. The work was supported by the Research Council of Norway Grant 223255/F50 through its Centres of Excellence funding scheme and by the National Institutes of Health Grants AI068730 and AI030040, and the European Community’s Seventh Framework Programme under Grant 602699 (DIREKT).

Disclosure

JDL is the inventor of patents and/or patent applications that describe the use of complement inhibitors for therapeutic purposes. He is also the founder of Amyndas Pharmaceuticals, which is developing complement inhibitors for clinical applications. The authors report no other conflicts of interest in this work.

References


Supplementary materials

**Figure S1** Schematic drawing of the IONPs received from Ocean Nanotech, LLC (Springdale, AR, USA). The particles are coated with a monolayer of oleic acid and amphiphilic polymer. The reactive group on the surface is carboxylic acid.

**Abbreviation:** IONPs, iron oxide nanoparticles.

**Figure S2** (Continued)

---

**IL-1β**

- 0 μg/mL Fe 10 nm
- 1 μg/mL Fe 10 nm
- 10 μg/mL Fe 10 nm
- 100 μg/mL Fe 10 nm

**IL-8**

**TNF**

**MCP-1**
Figure S2 Time-dependent cytokine (IL-1β, TNF, IL-6) and chemokine (IL-8, MCP-1, MIP-1β) response in plasma after incubation of lepirudin anti-coagulated human whole blood with PBS and IONPs.

Notes: Data are expressed as mean ± standard error of the mean (n=3) of separate experiments with different donors. *Statistical significance (P<0.05) compared with untreated PBS control at each time point.

Abbreviation: IONPs, iron oxide nanoparticles; PBS, phosphate-buffered saline.

Figure S3 The effect of complement inhibitors compstatin analog Cp40 and eculizumab on the production of sC5b-9 in plasma after 6 h incubation of anti-coagulated human whole blood with PBS and Zymosan (positive control for complement activation). Results from one experiment are shown.

Abbreviation: PBS, phosphate-buffered saline.